• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia to Present at the Emerging Growth Conference in December

    12/2/24 8:01:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email

    CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.

    MetaVia Logo

    After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to [email protected], or ask your questions during the event.

    Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at [email protected].

    About MetaVia

    MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

    For more information, please visit www.metaviatx.com.

    Contacts:

    MetaVia

    Marshall H. Woodworth

    Chief Financial Officer

    +1-857-299-1033

    [email protected]

    Rx Communications Group

    Michael Miller

    +1-917-633-6086

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-the-emerging-growth-conference-in-december-302317541.html

    SOURCE MetaVia Inc.

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When is MetaVia Inc. scheduled to present their company update?

      MetaVia Inc. is set to present at the Emerging Growth Conference on December 4, 2024, at 4:10 pm ET.

    • Who will be presenting during the Emerging Growth Conference for MetaVia Inc.?

      The presentation will be given by Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, Chief Financial Officer of MetaVia.

    • What are the primary products under development by MetaVia Inc.?

      MetaVia Inc. develops treatments for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), with DA-1726 and DA-1241 as their primary focus.

    • Will there be a Q&A session after the presentation, and how can attendees submit their questions?

      Following the presentation on December 4, management will accept questions from attendees, either submitted in advance or asked during the event.

    • How can one attend the Emerging Growth Conference and stay updated on MetaVia's presentation?

      Individuals interested in attending the conference can register via a provided link to receive updates and join the virtual event.

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H was granted 28,000 shares, increasing direct ownership by 1,024% to 30,734 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:02:10 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kim Hyung Heon was granted 32,000 shares, increasing direct ownership by 577% to 37,545 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:01:16 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Woodworth Marshall H gifted 14,200 shares, decreasing direct ownership by 32% to 30,079 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    8/13/25 4:36:41 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET. After the presentation, MetaVia management will open the floor for questions. Please submit your questions in ad

    2/17/26 9:01:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

    Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and intern

    2/13/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

    DeepMatcher® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes CAMBRIDGE, Mass., Feb. 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today provided an update on its ongoing collaboration with Syntekabio, Inc., an artificial intelligence (AI)-driven drug discovery company, leveraging their proprietary DeepMatcher® platform. Using AI-based compound-protein interaction modeling, Syntekabio has identif

    2/4/26 8:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    SEC Filings

    View All

    MetaVia Inc. filed SEC Form 8-K: Leadership Update

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/27/26 4:01:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    1/16/26 4:05:21 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by MetaVia Inc.

    424B4 - MetaVia Inc. (0001638287) (Filer)

    1/16/26 8:36:51 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care